The Food and Drug Administration (FDA) said it had received six reports of cases in 6.8 million doses of the Johnson & Johnson Covid-19 vaccine and was acting “out of an abundance of caution.”
Johnson & Johnson also mentioned that vaccine rollout in Europe will be delayed.
Related rare cases in the AstraZeneca vaccine have caused certain restrictions in its use in the United States..
The Johnson & Johnson jab was approved in the US on 27 February and its use has been more limited so far than that of the Pfizer-BioNTech and Moderna doses.
Nevertheless, the government had hoped for hundreds of thousands of vaccinations of the jab every week as it is single-shot and its storage at common refrigerator temperatures makes it easier to distribute.
In a joint statement, the FDA and the Centers for Disease Control and Prevention (CDC) said they were “reviewing data involving six reported US cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine”.
It said the clotting was called cerebral venous sinus thrombosis (CVST).
The statement said that this type of blood clot needed a different treatment than usual.
The common treatment – an anticoagulant drug called heparin – “may be dangerous”, it said.
Pending a further review, the FDA and CDC recommended “a pause in the use of this vaccine out of an abundance of caution”.
This was to “ensure that the health care provider community is aware of the potential for these adverse events”.
All six cases were in women aged between 18 and 48, with symptoms six to 13 days after vaccination.
The New York Times quoted officials as saying one woman had died and a second, in Nebraska, was in a critical condition.
The joint statement said that “people who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider”.
The federal government is now likely to pause the use of the vaccine in all federally run vaccination sites, and to expect state sites to do the same.
Johnson & Johnson statement
Johnson & Johnson, a health-care corporation based in the United States, released a statement stating that protection was its “top priority” and that it communicated “all adverse incident data” with health authorities.
It added: “We are aware that thromboembolic events including those with thrombocytopenia have been reported with Covid-19 vaccines. At present, no clear causal relationship has been established between these rare events and the Janssen (J&J) Covid-19 vaccine.”
It also said that it had been reviewing cases with European health authorities.
“We have made the decision to proactively delay the rollout of our vaccine in Europe,” it said.
Source: BBC NEWS